KA
KA Real Time Price USDRecent trades of KA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by KA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Proteasome activity enhancing compounds Apr. 16, 2024
-
Patent Title: Anti-viral compounds May. 01, 2018
-
Patent Title: Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Feb. 06, 2018
-
Patent Title: Anti-viral compounds Jan. 31, 2017
-
Patent Title: Methods and cells for identifying rig-i pathway regulators Oct. 04, 2016
-
Patent Title: Isoflavone anti-viral compounds Aug. 09, 2016
-
Patent Title: Diarylpyridine anti-viral compounds Apr. 05, 2016
-
Patent Title: Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Aug. 25, 2015
-
Patent Title: Anti-viral compounds Jul. 07, 2015
-
Patent Title: Pyrimidinedione anti-viral compounds Jan. 06, 2015
-
Patent Title: Sulfonamide anti-viral compounds Nov. 25, 2014
-
Patent Title: Iminochromene anti-viral compounds Oct. 28, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of KA in WallStreetBets Daily Discussion
Recent insights relating to KA
Recent picks made for KA stock on CNBC
ETFs with the largest estimated holdings in KA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view KA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.